Canny Susan, Mellins Elizabeth
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA.
F1000Res. 2017 Jun 22;6:971. doi: 10.12688/f1000research.11327.1. eCollection 2017.
Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines, such interleukins 1 and 6, has changed the treatment paradigm for sJIA patients. In this review, we discuss the therapies currently used in the treatment of sJIA as well as novel targets and approaches under consideration, including mesenchymal stromal cell therapy and JAK inhibitors. We also discuss targeting cytokines that have been implicated in MAS, such as interferon gamma and interleukin 18.
全身型幼年特发性关节炎（sJIA）及其最严重的并发症巨噬细胞活化综合征（MAS），传统上一直使用类固醇和非甾体类抗炎药物进行治疗。然而，抑制特定细胞因子（如白细胞介素1和6）的生物药物的引入，改变了sJIA患者的治疗模式。在本综述中，我们讨论了目前用于治疗sJIA的疗法以及正在考虑的新靶点和方法，包括间充质基质细胞疗法和JAK抑制剂。我们还讨论了针对与MAS相关的细胞因子，如干扰素γ和白细胞介素18。
